Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.5.4 replaces the previous v3.5.3, indicating an updated page build without changes to displayed content.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe study record dates have been updated to include new entries (2026-05-01, 2027-02-25, 2026-04-17, 2026-04) and remove earlier entries (2025-05-07, 2026-03-25, 2025-04-29, 2025-04), reflecting adjustments to the posting and QC timeline on the page.SummaryDifference0.2%

- Check25 days agoChange DetectedThe page version/build indicator was updated from v3.5.2 to v3.5.3, reflecting a minor administrative release rather than a substantive change to the trial’s study details.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check61 days agoChange Detected- Updated page revision from v3.4.3 to v3.5.0. This appears to be an administrative update and does not modify study details or eligibility criteria.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 as part of a site update. This change does not modify study information or how users interact with the page.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.